Regulatory

CLINUVEL
Posted by CLINUVEL
January 27, 2023

Technical Note: Developing a melanocortin pipeline

CLINUVEL today announced an update on its commercial development of the analogue...

Read More
CLINUVEL
Posted by CLINUVEL
January 23, 2023

NEURACTHEL® manufacturing processes advance

CLINUVEL today announced an update on its commercial development of the analogue...

Read More
CLINUVEL
Posted by CLINUVEL
January 16, 2023

Media release: CLINUVEL Trial Results Show Drug Reduces DNA Damage

Results from a clinical trial in a genetic DNA repair disorder show...

Read More
CLINUVEL
Posted by CLINUVEL
January 16, 2023

Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum - Technical Note

Melbourne, Australia, 16 January 2023 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
January 16, 2023

Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum

Melbourne, Australia, 16 January 2023 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
December 21, 2022

Notification of cessation of securities

Melbourne, Australia, 21 December 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
November 7, 2022

Appendix 3Y - Change of Director’s Interest Notice

Melbourne, Australia, 07 November 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
October 31, 2022

Appendix 4C & Activity Report

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...

Read More
CLINUVEL
Posted by CLINUVEL
October 20, 2022

First vitiligo patient enrolled in afamelanotide monotherapy study

CUV104 study to evaluate the role of afamelanotide as monotherapy in patients...

Read More
CLINUVEL
Posted by CLINUVEL
September 23, 2022
CLINUVEL
Posted by CLINUVEL
September 8, 2022

CLINUVEL confirms AGM date

CLINUVEL confirms the date for the Company’s 2022 Annual General Meeting.

Read More
Lachlan Hay
Posted by Lachlan Hay
September 5, 2022

CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients

European regulatory submission follows clinical support for SCENESSE® treatment in EPP patients...

Read More
CLINUVEL
Posted by CLINUVEL
August 31, 2022

CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2022

CLINUVEL PHARMACEUTICALS LTD hosted an investor webinar on the financial results for...

Read More
CLINUVEL
Posted by CLINUVEL
August 30, 2022

Appendix 4G

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4G

Read More
CLINUVEL
Posted by CLINUVEL
August 30, 2022

Revenue Growth Drives CLINUVEL's Sixth Consecutive Annual Profit

CLINUVEL today announced its sixth consecutive annual net profit, driven by revenues...

Read More